SABCS 2024 | Optimizing antibody-drug conjugates with computational modelling
Melissa Calopiz
• 12 Dec 2024
Melissa Calopiz, University of Michigan, Ann Arbor, MI, explores the use of SimADC, a computational model for designing and evaluating antibody-drug conjugates (ADCs). By simulating immune cell interactions and payload release mechanisms, this approach aims to enhance ADC design, reduce toxicity, and improve therapeutic outcomes, especially in low-expression systems like those treated with trastuzumab deruxtecan. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
